ERYSIPELOTHRIX RHUSIOPATHIAE (SWINE ERYSIPELAS)
LEVELS: Highly unlikely: No controls necessary; Occupational exposure risk: Non-foodborne transmission pathway(s) that are strongly associated with occupational exposure and can lead to human infection; Highly effective: Routine on-farm biosecurity measures are effective in preventing farm-to-farm transmission; Easy: Distinct clinical signs and/or existing test(s) available at local/regional laboratory(s); Substantial: Unsustainable acute or chronic losses related to severe clinical signs in a high prevalence of animals; Negligible: Little or no market disruption when disease occurs on one or more farms; Moderate risk: Evidence of development of clinically important resistance to antibacterial or antiviral treatments, or that development of such resistance is likely to occur over time; Moderate risk: Antibacterial or antiviral treatments are commonly used for treating affected individuals; Available but with uncertain efficacy: Limited treatments available in US or are only effective in some situations; Widely available: Effective commercial vaccines widely available in the US (or held in national response stockpile); Highly likely: Can be eradicated using existing tools and knowledge
OVERVIEW
Erysipelothrix rhusiopathiae is a nonmotile, non-sporulating, facultative intracellular gram-positive rod that causes swine erysipelas, a disease first characterized by Pasteur (1882) and Löffler (1886). The organism has global distribution and is ubiquitous, with the domestic pig serving as the most important reservoir. Approximately 30-50% of healthy pigs harbor E. rhusiopathiae in their tonsils and lymphoid tissues. The disease presents in three clinical forms: acute (septicemic with characteristic "diamond skin" lesions, sudden death, fever up to 42°C), subacute (milder with variable skin lesions), and chronic (arthritis, vegetative valvular endocarditis). In naive herds, acute outbreaks can cause 20-40% mortality. Based on cell wall antigens, strains are differentiated into at least 28 serotypes, with serotypes 1a, 1b, and 2 causing most clinical cases. E. rhusiopathiae is highly susceptible to penicillin, which remains the treatment of choice. Vaccination with bacterins or attenuated live vaccines is generally effective, providing 6-12 months of immunity. The organism is zoonotic, causing "erysipeloid" in humans—a localized cutaneous infection primarily affecting those with occupational exposure (butchers, veterinarians, farmers). E. rhusiopathiae can persist in the environment for months under favorable conditions but is inactivated by common disinfectants.
FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No controls necessary
Foodborne transmission to humans is not documented. Human erysipeloid results from direct contact with infected animals or contaminated materials, not from consumption of pork products: "Most human cases are a consequence of occupational exposure...to infected animals or their tissues and occur via scratches or traumatic penetration of the skin." Proper cooking would inactivate the organism, and there are no reports of foodborne outbreaks.
NON-FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Occupational exposure risk: Non-foodborne transmission pathway(s) that are strongly associated with occupational exposure and can lead to human infection
E. rhusiopathiae is a recognized occupational zoonosis: (1) Occupational exposure: "Most human cases are a consequence of occupational exposure (butchers, abattoir workers, veterinarians, farmers, fishermen, fish handlers, and domestic food preparers)"; (2) Transmission route: Infection occurs "via scratches or traumatic penetration of the skin"; (3) Clinical manifestation: "The clinical form in humans is called erysipeloid and manifests as acute localized cellulitis with skin reddening"; (4) Serious forms: "Additional clinical presentations include a generalized cutaneous form and a septicemic form, with endocarditis present in about one third of patients"; (5) Occupational names: Known as "whale finger," "seal finger," "pork finger," etc.; (6) No human-to-human: "Human-to-human transmission of E. rhusiopathiae has not been established to date."
EFFECTIVENESS OF ON-FARM BIOSECURITY IN PREVENTING FARM-TO-FARM TRANSMISSION
Level: Highly effective: Routine on-farm biosecurity measures are effective in preventing farm-to-farm transmission
While widespread, disease is controllable through standard management: (1) High carriage rate: "Approximately 30–50% of apparently healthy pigs harbor E. rhusiopathiae in their tonsils and other lymphoid tissues"; (2) Transmission routes: "Transmission...is believed to occur directly via oronasal secretions and feces, and indirectly via ingestion of contaminated feed or water and through contamination of skin wounds"; (3) Environmental persistence: "persisting for up to several months under certain conditions" but "E. rhusiopathiae is inactivated by commonly available disinfectants"; (4) No significant wildlife introduction: Wild boar can carry E. rhusiopathiae but "transmission between wild boars and domestic pigs appears to be infrequent"; (5) Control achievable: Vaccination and sanitation effectively control disease on farms.
DIFFICULTY OF DETECTING AND CONFIRMING INFECTION
Level: Easy: Distinct clinical signs and/or existing test(s) available at local/regional laboratory(s)
Multiple validated diagnostic methods are available: (1) Clinical diagnosis: "nearly pathognomonic gross lesions of acute swine erysipelas consist of multifocal pink to purple rhomboid (diamond-shaped) slightly raised skin lesions"; (2) Culture: "Isolation of Erysipelothrix spp. from tissues with morphological lesions provides a definitive laboratory diagnosis"; "Direct culture from noncontaminated specimens is usually fast and easy"; (3) PCR: Multiple methods available including "genus-specific methods," "multiplex PCR assay capable of differentiating between E. rhusiopathiae and E. tonsillarum," and "quantitative real-time multiplex assay"; (4) Immunohistochemistry: "highly sensitive and specific when compared to direct culture techniques"; (5) Serology: "Serological assays, including plate, tube, and microtitration agglutination...enzyme-linked immunosorbent assays (ELISA)...have been used"; (6) Turnaround: Culture 24-72 hours; PCR 3-6 hours.
FINANCIAL IMPACT ON FARM'S COST OF PRODUCTION
Level: Substantial: Unsustainable acute or chronic losses related to severe clinical signs in a high prevalence of animals
Swine erysipelas causes substantial economic losses: (1) High acute mortality: "In outbreaks of acute swine erysipelas in naive herds, mortality can quickly rise to 20–40%"; (2) Sudden death: "The greatest losses can be attributed to cases of sudden death and acute septicemia in grower-finisher pigs"; (3) Chronic sequelae: "A frequent sequela of surviving an acute infection is chronic lameness and arthritis, which results in poor growth and abattoir condemnations"; (4) All production stages: Disease is "capable of affecting all stages of pork production"; (5) Reproductive losses: "There may be infertility, litters with increased numbers of mummies or of small size, and pre- or postparturient vulvar discharges"; (6) Cyclic outbreaks: "more severe and prevalent outbreaks occur in recurring intervals of approximately 10 years"; (7) Re-emergence concerns: "Several recent reports of swine erysipelas outbreaks in countries with relevant pig production raise concerns on re-emergence of this disease."
EFFECT ON DOMESTIC OR EXPORT MARKETS
Level: Negligible: Little or no market disruption when disease occurs on one or more farms
E. rhusiopathiae has minimal trade impact: (1) Not regulated: Not a WOAH-listed or nationally regulated disease for trade purposes; (2) Endemic worldwide: "Erysipelothrix rhusiopathiae has a global distribution and is ubiquitous"; (3) Abattoir condemnations: Chronic arthritis results in condemnations but doesn't affect market access; (4) No trade restrictions: Positive status does not trigger export bans or movement restrictions.
PATHOGEN'S ABILITY TO DEVELOP AND SPREAD RESISTANCE
Level: Moderate risk: Evidence of development of clinically important resistance to antibacterial or antiviral treatments, or that development of such resistance is likely to occur over time
Antimicrobial resistance is emerging but penicillin remains effective: (1) Penicillin susceptible: "E. rhusiopathiae is highly susceptible to penicillin, which remains the treatment of choice"; (2) Emerging resistance: "use of antimicrobials, such as tetracycline, erythromycin, lincosamides (clindamycin), and quinolones (enrofloxacin, ciprofloxacin), should be limited, given the increasing reports of bacterial resistance"; (3) Resistance mechanisms identified: "resistance to enrofloxacin has been correlated to mutations in the gyrA and parC genes"; "Resistance to tetracycline has been identified from mutations in the tet(M) and Tn96/Tn1 transposon integrase genes"; "erm(T) and erm(A)-like genes have been detected in macrolide-resistant...strains"; (4) Continued monitoring needed: Multiple resistance genes identified across different drug classes.
AMR DEVELOPMENT DRIVEN BY DISEASE MANAGEMENT
Level: Moderate risk: Antibacterial or antiviral treatments are commonly used for treating affected individuals
Disease management drives moderate antimicrobial use: (1) Treatment standard: "Antimicrobial therapy early in the course of E. rhusiopathiae infection usually results in a good response in the affected pig within 24–36 hours"; (2) Chronic treatment ineffective: "therapy during the chronic course of erysipelas is usually ineffective due to structural damage in joints and the endocardium"; (3) Outbreak treatment: Acute outbreaks require treatment of affected animals; (4) Vaccination reduces need: "Prevention of swine erysipelas is best accomplished by immunization programs"—reducing antimicrobial pressure in well-vaccinated herds.
AVAILABILITY OF EFFECTIVE TREATMENT OPTIONS
Level: Available but with uncertain efficacy: Limited treatments available in US or are only effective in some situations
Penicillin treatment is highly effective for acute disease: (1) Penicillin first choice: "E. rhusiopathiae is highly susceptible to penicillin, which remains the treatment of choice"; (2) Rapid response: "Antimicrobial therapy early in the course of E. rhusiopathiae infection usually results in a good response in the affected pig within 24–36 hours"; (3) Chronic limitations: "therapy during the chronic course of erysipelas is usually ineffective due to structural damage in joints and the endocardium"; (4) Antiserum historical: "Therapy with antiserum has been widely used as treatment for acute septicemia"—though less common now with effective antibiotics.
AVAILABILITY OF EFFECTIVE VACCINES OR BACTERINS
Level: Widely available: Effective commercial vaccines widely available in the US (or held in national response stockpile)
Vaccination is effective and widely used: (1) Vaccine types: "Current vaccines are based on E. rhusiopathiae serotypes 1 or 2 and are either inactivated bacterins for intramuscular injection or attenuated (avirulent live) vaccines designed for whole herd mass treatment via the drinking water"; (2) Efficacy: "Vaccination is generally effective in preventing swine erysipelas"; (3) Duration of immunity: "6 and to 12 months for both correctly administered bacterins and avirulent vaccines"; (4) Cross-protection: "Pigs vaccinated with a live serotype 2 vaccine were protected against clinical erysipelas when challenged with serotypes 1a, 1b, 2, 5, 8, 11, 12, 18, 19, or 21"; (5) Breeding herd benefits: "Immunization programs can target growing pigs, breeding herds, or both"; vaccination "reduces the incidence of periparturient vulvar discharge, decreases farrowing intervals, and increases the numbers of live-born pigs"; (6) Combination vaccines: Available combined with PRRSV and PPV for single injection in breeding herds; (7) Limitation: "Vaccination may not be as effective in preventing chronic arthritis since sequestration of E. rhusiopathiae in the cytoplasm of chondrocytes...may provide protection from host immunity."
FEASIBILITY OF ERADICATING THE DISEASE FROM THE US
Level: Highly likely: Can be eradicated using existing tools and knowledge
Herd-level elimination is achievable; national eradication is unnecessary: (1) Herd elimination: "Negative herds can be established by cesarean derivation or medicated early weaning"; (2) Reinfection risk: "given the ubiquity of E. rhusiopathiae, it is unlikely that negative herds can be maintained for extended periods of time"; (3) Control sufficient: Effective vaccines and treatments make formal eradication unnecessary; (4) Environmental persistence: Organism survives in environment but is susceptible to disinfectants; (5) Widespread carriage: 30-50% of healthy pigs are carriers, making elimination impractical; (6) Practical approach: Vaccination-based control is the standard approach rather than eradication.